Improvements In ADC Efficacy And Stability Through Proprietary Hydrophilic Linker Platform

Antibody-drug conjugates (ADCs) are transforming oncology by combining the targeting specificity of monoclonal antibodies with highly potent cytotoxic payloads. However, as ADC payloads become more powerful, they are also often more hydrophobic, creating significant challenges for developers. Increased hydrophobicity can lead to aggregation, reduced solubility, and instability, all of which can negatively affect drug performance and manufacturability during process development and scale-up. These issues may also influence conjugation efficiency, purification behavior, product stability, and overall process robustness across ADC programs.

Hydrophobicity is closely tied to the drug-to-antibody ratio (DAR), a key parameter in ADC design. While low DAR can limit the amount of payload delivered to target cells and reduce therapeutic potency, excessively high DAR may worsen physicochemical properties, leading to aggregation, faster systemic clearance, reduced exposure, and a greater risk of toxicity or immunogenicity. Balancing potency with favorable developability characteristics has therefore become a central focus in next-generation ADC design.

To address these challenges, developers are increasingly exploring hydrophilic linker strategies. By offsetting payload-derived hydrophobicity, these linkers can improve ADC solubility, stability, and pharmacokinetic profiles. As ADC pipelines continue to expand and payload complexity increases, optimizing linker design will remain an important strategy for enabling the successful development and scalable manufacturing of advanced ADC therapeutics.